Convert Pharmaceuticals

Convert Pharmaceuticals is an SME in Liege, Belgium that has taken part in 1 EU-funded project since 2024, receiving €2.5M in EU funding and leading 1 as coordinator.

EU funding received€2.5M
EU projects1
As coordinator1
Running now0
First EU project2024
Latest project2024
CountryBelgium
EU registration (PIC)903132566
On this page · 4 sections→

Where the EU money came from

Funding by EU programme. Amounts are Convert Pharmaceuticals's own share of each project, not the project's full budget.

  • Horizon Europe€2.5M · 1 project

Projects

1 EU-funded project, newest first. Convert Pharmaceuticals led 1 of them as coordinator. Each links to the official record.

  • TUMAGNOSTICCoordinator

    A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach

    Horizon Europe · 2024–2025 · Project on CORDIS ↗

    €2.5Mtheir share

Fields it works in

Research fields recorded on its Horizon projects.

  • oncology

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime